BE574826A - - Google Patents
Info
- Publication number
- BE574826A BE574826A BE574826DA BE574826A BE 574826 A BE574826 A BE 574826A BE 574826D A BE574826D A BE 574826DA BE 574826 A BE574826 A BE 574826A
- Authority
- BE
- Belgium
- Prior art keywords
- streptokinase
- column
- solution
- purified
- high purity
- Prior art date
Links
- XRZWVSXEDRYQGC-UHFFFAOYSA-N 4-cyclohexylpyrrolidin-1-ium-2-carboxylate Chemical compound C1NC(C(=O)O)CC1C1CCCCC1 XRZWVSXEDRYQGC-UHFFFAOYSA-N 0.000 claims description 92
- 229960005202 Streptokinase Drugs 0.000 claims description 92
- 108010023197 Streptokinase Proteins 0.000 claims description 92
- 239000001913 cellulose Substances 0.000 claims description 24
- 229920002678 cellulose Polymers 0.000 claims description 24
- 238000010828 elution Methods 0.000 claims description 19
- 238000004062 sedimentation Methods 0.000 claims description 12
- 208000007536 Thrombosis Diseases 0.000 claims description 9
- 239000007853 buffer solution Substances 0.000 claims description 7
- 238000009792 diffusion process Methods 0.000 claims description 7
- 239000008363 phosphate buffer Substances 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 6
- 238000001962 electrophoresis Methods 0.000 claims description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 3
- 239000010452 phosphate Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 25
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 22
- 239000000047 product Substances 0.000 description 15
- 238000000034 method Methods 0.000 description 14
- 229910000162 sodium phosphate Inorganic materials 0.000 description 13
- 210000004369 Blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 229910052757 nitrogen Inorganic materials 0.000 description 11
- 239000000203 mixture Substances 0.000 description 10
- 239000001488 sodium phosphate Substances 0.000 description 9
- 235000011008 sodium phosphates Nutrition 0.000 description 9
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000000463 material Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000002588 toxic Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 102000037197 Anion exchangers Human genes 0.000 description 4
- 108091006437 Anion exchangers Proteins 0.000 description 4
- 229960004533 Streptodornase Drugs 0.000 description 4
- 239000003463 adsorbent Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000001747 exhibiting Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 230000037230 mobility Effects 0.000 description 4
- 235000019799 monosodium phosphate Nutrition 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 229950003499 FIBRIN Drugs 0.000 description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 3
- 102000009123 Fibrin Human genes 0.000 description 3
- 108010073385 Fibrin Proteins 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000005484 gravity Effects 0.000 description 3
- 230000033458 reproduction Effects 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- YMDNODNLFSHHCV-UHFFFAOYSA-N 2-chloro-N,N-diethylethanamine Chemical compound CCN(CC)CCCl YMDNODNLFSHHCV-UHFFFAOYSA-N 0.000 description 2
- 229940088598 Enzyme Drugs 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229940012957 Plasmin Drugs 0.000 description 2
- 102000013566 Plasminogen Human genes 0.000 description 2
- 108010051456 Plasminogen Proteins 0.000 description 2
- 108091006544 SLC13A2 Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 230000003213 activating Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000001143 conditioned Effects 0.000 description 2
- 230000003247 decreasing Effects 0.000 description 2
- 238000003795 desorption Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 230000005499 meniscus Effects 0.000 description 2
- 230000000896 plasminic Effects 0.000 description 2
- 230000001376 precipitating Effects 0.000 description 2
- 230000002335 preservative Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000001698 pyrogenic Effects 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000563 toxic property Toxicity 0.000 description 2
- 229960001322 trypsin Drugs 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 210000001772 Blood Platelets Anatomy 0.000 description 1
- 206010005746 Blood pressure fluctuation Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-K Disodium phosphate Chemical compound [Na+].[Na+].[O-]P([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-K 0.000 description 1
- 229940110715 ENZYMES FOR TREATMENT OF WOUNDS AND ULCERS Drugs 0.000 description 1
- 101700029812 FIBR Proteins 0.000 description 1
- 229960002897 Heparin Drugs 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N Heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010025482 Malaise Diseases 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 210000004915 Pus Anatomy 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- FKHIFSZMMVMEQY-UHFFFAOYSA-N Talc Chemical compound [Mg+2].[O-][Si]([O-])=O FKHIFSZMMVMEQY-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 230000002429 anti-coagulation Effects 0.000 description 1
- 230000001754 anti-pyretic Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000000890 antigenic Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940019336 antithrombotic Enzymes Drugs 0.000 description 1
- 239000012446 aqueous acidic reagent Substances 0.000 description 1
- 230000001174 ascending Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 230000003683 cardiac damage Effects 0.000 description 1
- 210000004027 cells Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000003750 conditioning Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000003480 fibrinolytic Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229940020899 hematological Enzymes Drugs 0.000 description 1
- 230000002949 hemolytic Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002934 lysing Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- 230000002797 proteolythic Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N silicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 201000005060 thrombophlebitis Diseases 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
- C07K14/3153—Streptokinase
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE574826A true BE574826A (de) |
Family
ID=190768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE574826D BE574826A (de) |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE574826A (de) |
-
0
- BE BE574826D patent/BE574826A/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4170590A (en) | Ion exchanger treatment of citrate-stabilized plasma | |
| EP0503991B1 (de) | Verfahren zur Herstellung in industriellem Massstab eines Konzentrates von hochgereinigtem, standardisiertem humanen von Willebrand Faktor, das für therapeutische Anwendung geeignet ist | |
| FR2576752A1 (fr) | Procede de purification de proteines du lait et de ses derives | |
| JPS6160049B2 (de) | ||
| EP0416983A1 (de) | Verfahren zur Herstellung eines Konzentrats des Faktor VIII-von Willebrand-Faktor-Komplexes der Blutgerinnung aus Vollplasma | |
| US4555344A (en) | Method of size-selective extraction from solutions | |
| CH668428A5 (fr) | Procede d'extraction de proteines du lait, produits, application du procede et compositions pharmaceutiques. | |
| US2983647A (en) | Urokinase and method of recovering the same | |
| CH626808A5 (de) | ||
| JP2000506843A (ja) | セルロース系ろ過助剤を使用する血漿混合物のろ過 | |
| EP0023860A2 (de) | Verfahren zur Herstellung eines Plasminogenaktivators, so erhaltener Aktivator und ihn enthaltendes Arzneimittel | |
| US4692331A (en) | Gamma-globulin preparation for intravenous administration | |
| JP2008541731A (ja) | トロンビンの精製 | |
| BE574826A (de) | ||
| JP3946747B2 (ja) | ラクトパーオキシダーゼの製造方法 | |
| JP2011195611A (ja) | ヒアルロン酸及び／又はその塩の精製法 | |
| US3907777A (en) | Method of removing vitamin B{HD 2 {B from whey | |
| CN105002153B (zh) | 一种凝血酶的制备方法 | |
| FR2473886A1 (fr) | Perfectionnement aux procedes de concentration et de purification du facteur anti-hemophilique (facteur viii) et preparations de facteur viii concentre et purifie obtenues | |
| US3444045A (en) | Process for purifying streptokinase | |
| US5244807A (en) | Production of pseudomonas xa cells containing indolyl-3-alkane alpha-hydroxylase | |
| CN115739031B (zh) | 壳聚糖或其衍生物在脱除明胶中内毒素的应用 | |
| RU2143267C1 (ru) | Способ очистки белков плазмы от липопротеинов (его варианты) | |
| KR0149793B1 (ko) | 고분자량 히알우론산의 정제방법 | |
| KR790001376B1 (ko) | 우로키나제의 정제 및 회수법 |